Are newer, targeted agents better for the management of untreated CLL than chemoimmunotherapy?
Description: The targeted agent ibrutinib has been tested as a first-line monotherapy in elderly chronic lymphocytic leukemia (CLL) in the RESONATE-2 trial (NCT01722487); however, within CLL, it has not been tested in combination or in younger patients. Here, Jacqueline Barrientos, MD, of the Feinstein Institute for Medical Research, Manhasset, NY, discusses the Phase III E1912 trial (NCT02048813), which is investigating the combination of ibrutinib and rituximab vs. classic fludarabine, cyclophosphamide and rituximab (FCR) for CLL. Dr Barrientos provides an update on the highly-anticipated trial and highlights how the results will aid in the determination of whether newer, targeted agents are better for the treatment of untreated CLL compared with chemoimmunotherapy. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Shared By : VJHemOnc
Posted on : 01/08/18
Added : 1 year ago